[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356380-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356380-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","linc00467-mediates-parp-inhibitor-resistance-in-high-grade-serous-ovarian-cancer-by-regulating-mir-485-5prad50-axis","LINC00467 mediates PARP inhibitor resistance in high-grade serous ovarian cancer by regulating miR-485-5p/RAD50 axis","","High-grade serous ovarian cancer remains highly lethal due to frequent recurrence and resistance to chemotherapy, while PARP inhibitors show promise but resistance mechanisms are unclear. This study investigates the molecular basis of PARP inhibitor resistance and evaluates LINC00467 as a therapeutic target. Olaparib-acquired resistant cell models, lncRNA sequencing, functional assays, bioinformatics, a dual-luciferase system, and patient-derived xenograft validation are used.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/linc00467-mediates-parp-inhibitor-resistance-in-high-grade-serous-ovarian-cancer-by-regulating-mir-485-5prad50-axis/356380/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/linc00467-mediates-parp-inhibitor-resistance-in-high-grade-serous-ovarian-cancer-by-regulating-mir-485-5prad50-axis/356380.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the study?","Question",{"text":63,"@type":64},"To investigate the mechanism of PARP inhibitor (PARPi) resistance and explore new therapeutic targets in high-grade serous ovarian cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were PARPi-resistant models created and validated?",{"text":68,"@type":64},"Olaparib-acquired resistant cell lines (SKOV3-OR) were generated, and patient-derived xenograft (PDX) models were established to validate the effects of LINC00467 on olaparib response.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism does LINC00467 use to influence PARPi resistance?",{"text":72,"@type":64},"LINC00467 acts as a competitive endogenous RNA by directly sponging miR-485-5p, which then regulates its downstream target RAD50, contributing to PARPi resistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356380,1790186986,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Li et al. Journal of Ovarian Research (2026) 19:71 [https://doi.org/10.1186/s13048-026-01971-9](https://doi.org/10.1186/s13048-026-01971-9)  \nJournal of Ovarian Research  \nRESEARCH Open Access  \nLINC00467 mediates PARP inhibitor resistance in high-grade serous ovarian cancer by regulating miR-485-5p/RAD50 axis  \nXin Li1†, Yi Xiang2†, Jie Gao1, Hui Zong1, Miao Li1, Renzhuo Gao1 and Hui Zhang1*  \nAbstract  \nPurpose High-grade serous ovarian cancer (HGSOC) is extremely lethal owing to its high risk of recurrence and resistance to common chemotherapy. PARP inhibitor (PARPi) is currently the most promising target drug among patients with HGSOC, but its resistance mechanism remains unclear. In this study, we aimed to investigate the mechanism of PARPi resistance and explore new therapeutic targets.  \nMethods We established olaparib-acquired resistant cell lines denoted SKOV3-OR and performed lncRNA sequencing. Biological behavior study illustrated the effect of LINC00467 on HGSOC cells in vitro and vivo. Bioinformatics and the dual-luciferase reporter system confirmed the downstream target genes. Patient-derived xenograft (PDX) models were established to validate the effect of LINC00467 on response to olaparib.  \nResults LncRNA sequencing revealed that LINC00467 was upregulated in PARPi resistant HGSOC cell and predicted poor prognosis. Biological behavior study comfirmed LINC00467 promoted cell proliferation, metastasis and PARPi resistance in HGSOC. Furthermore, the dual-luciferase reporter system confirmed its function as a competitive endogenous RNA by directly sponging miR-485-5p, which further regulated its target, RAD50 . Additionally, LINC00467 ASO played a synergistic role with olaparib in HGSOC PDX models.  \nConclusion Our results showed that LINC00467 could confer PARPi resistance in HGSOC by regulating the miR- 485-5p/RAD50 axis and provide a novel therapeutic target in PARPi synergistic treatment for HGSOC.  \nKeywords HGSOC, PARP inhibitor, LINC00467, miR-485-5p, RAD50, PDX model  \n†Xin Li and Yi Xiang contributed equally to this work.  \n*Correspondence: Hui Zhang [williamzh@126.com](williamzh@126.com)  \n1Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, 107 Wenhua West Road, Ji’nan, Shandong 250012, P. R. China 2Independent Researcher, Ji’nan, Shandong 250000, P. R. China  \nIntroduction  \nHigh-grade serous ovarian cancer (HGSOC) is a common malignant tumor in women with a high lethal rate (90%) and its 5-year survival rate is less than 30% [1] because most patients are diagnosed at an advanced stage with frequent metastasis [2]. Moreover, almost 70% of patients relapse, although they have accepted standard cytoreductive surgery and chemotherapy because of chemotherapy resistance [3, 4]. Lu J et al. suggests that the prognosis of ovarian cancer patients may be related to Oxidative Phosphorylation (OXPHOS) [5]. Their study revealed that OXPHOS-related genes were considerably  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.","cbCais1aW0QRbkTP","https://ap.wps.com/l/cbCais1aW0QRbkTP","pdf",4353941,15,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n## High-grade serous ovarian cancer and PARP inhibitors\n## Long non-coding RNAs in cancer","[{\"question\":\"What is the main purpose of the study?\",\"answer\":\"To investigate the mechanism of PARP inhibitor (PARPi) resistance and explore new therapeutic targets in high-grade serous ovarian cancer.\"},{\"question\":\"How were PARPi-resistant models created and validated?\",\"answer\":\"Olaparib-acquired resistant cell lines (SKOV3-OR) were generated, and patient-derived xenograft (PDX) models were established to validate the effects of LINC00467 on olaparib response.\"},{\"question\":\"What mechanism does LINC00467 use to influence PARPi resistance?\",\"answer\":\"LINC00467 acts as a competitive endogenous RNA by directly sponging miR-485-5p, which then regulates its downstream target RAD50, contributing to PARPi resistance.\"}]","LINC00467 mediates PARP inhibitor resistance in high-grade serous ovarian cancer by regulating miR-485-5p/RAD50 axis | PDF",1790125105,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2912cfc5022ce22ebcd641951935bde9.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9699df651eb9bf8a6b9daac9f500133.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfaafa21e4111cc1c4baf1df38d30d5c.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fbb70d96ce57621e49b18703de2f3ca3.webp",980,1306]